Detlef Zillikens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Detlef Zillikens has a total of 312 co-authors. Here are the top co-authors by number of shared publications:
- Enno Schmidt
Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany
17 shared publications - Ralf Joachim Ludwig
Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany
8 shared publications - Katja Bieber
Lübeck Institute of Experimental Dermatology, University of Lübeck, 23562 Lübeck, Germany
7 shared publications - Christian David Sadik
Department of Dermatology, Allergy, and Venereology University of Lübeck Lübeck Germany
6 shared publications - Pascal Joly
Department of Dermatology, Rouen University Hospital, INSERM U1234 Normandie University , Rouen
5 shared publications - Saleh Mohamed Ibrahim
College of Medicine, Khalifa University, Abu Dhabi, UAE
5 shared publications
Latest Publications
- Open Access
- 14 February 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-17
Impact of diet and host genetics on the murine intestinal mycobiome
The mammalian gut is home to a diverse microbial ecosystem, whose composition affects various physiological traits of the host. Next-generation sequencing-based metagenomic approaches demonstrated how the interplay of host genetics, bacteria, and environmental factors shape complex traits and clinical outcomes. However, the role of fungi in these complex interactions remains understudied. Here, using 228 males and 363 females from an advanced-intercross mouse line, we provide evidence that fungi are regulated by host genetics. In addition, we map quantitative trait loci associated with various fungal species to single genes in mice using whole genome sequencing and genotyping. Moreover, we show that diet and its’ interaction with host genetics alter the composition of fungi in outbred mice, and identify fungal indicator species associated with different dietary regimes. Collectively, in this work, we uncover an association of the intestinal fungal community with host genetics and a regulatory role of diet in this ecological niche.
- 14 February 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-17
Open AccessImpact of diet and host genetics on the murine intestinal mycobiome
The mammalian gut is home to a diverse microbial ecosystem, whose composition affects various physiological traits of the host. Next-generation sequencing-based metagenomic approaches demonstrated how the interplay of host genetics, bacteria, and environmental factors shape complex traits and clinical outcomes. However, the role of fungi in these complex interactions remains understudied. Here, using 228 males and 363 females from an advanced-intercross mouse line, we provide evidence that fungi are regulated by host genetics. In addition, we map quantitative trait loci associated with various fungal species to single genes in mice using whole genome sequencing and genotyping. Moreover, we show that diet and its’ interaction with host genetics alter the composition of fungi in outbred mice, and identify fungal indicator species associated with different dietary regimes. Collectively, in this work, we uncover an association of the intestinal fungal community with host genetics and a regulatory role of diet in this ecological niche.
- Open Access
- 1 January 2023
- Published by XMLink in Annals of Dermatology
- Vol. 35 (1) , 61-65
Case Report of a Novel Association between Anti-p200 Pemphigoid and Acquired Haemophilia A
Koh XQ, et al. Ann Dermatol. 2023 Feb;35(1):61-65. https://doi.org/10.5021/ad.20.301
- 1 January 2023
- Published by XMLink in Annals of Dermatology
- Vol. 35 (1) , 61-65
Open AccessCase Report of a Novel Association between Anti-p200 Pemphigoid and Acquired Haemophilia A
Koh XQ, et al. Ann Dermatol. 2023 Feb;35(1):61-65. https://doi.org/10.5021/ad.20.301
- Open Access
- 20 August 2022
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 20 (S2) , 7-13
Poster
- 20 August 2022
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 20 (S2) , 7-13
Open AccessPoster
- Top Cited PapersOpen Access
- 29 June 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (10) , 1689-1704
UpdatedS2K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)
Background: Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or, most frequently, generalized bullous lesions. A subset of patients only develops excoriations, prurigo‐like lesions, and eczematous and/or urticarial erythematous lesions. The disease, which is significantly associated with neurological disorders, has high morbidity and severely impacts the quality of life.Objectives and methodology: The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology sought to update the guidelines for the management of BP based on new clinical information, and new evidence on diagnostic tools and interventions. The recommendations are either evidence‐based or rely on expert opinion. The degree of consent among all task force members was included.Results: Treatment depends on the severity of BP and patients' comorbidities. High‐potency topical corticosteroids are recommended as the mainstay of treatment whenever possible. Oral prednisone at a dose of 0.5 mg/kg/day is a recommended alternative. In case of contraindications or resistance to corticosteroids, immunosuppressive therapies, such as methotrexate, azathioprine, mycophenolate mofetil or mycophenolate acid, may be recommended. The use of doxycycline and dapsone is controversial. They may be recommended, in particular, in patients with contraindications to oral corticosteroids. B‐cell‐depleting therapy and intravenous immunoglobulins may be considered in treatment‐resistant cases. Omalizumab and dupilumab have recently shown promising results. The final version of the guideline was consented to by several patient organizations.Conclusions: The guidelines for the management of BP were updated. They summarize evidence‐ and expert‐based recommendations useful in clinical practice.
- 29 June 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (10) , 1689-1704
Top Cited PapersOpen AccessUpdatedS2K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)
Background: Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or, most frequently, generalized bullous lesions. A subset of patients only develops excoriations, prurigo‐like lesions, and eczematous and/or urticarial erythematous lesions. The disease, which is significantly associated with neurological disorders, has high morbidity and severely impacts the quality of life.Objectives and methodology: The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology sought to update the guidelines for the management of BP based on new clinical information, and new evidence on diagnostic tools and interventions. The recommendations are either evidence‐based or rely on expert opinion. The degree of consent among all task force members was included.Results: Treatment depends on the severity of BP and patients' comorbidities. High‐potency topical corticosteroids are recommended as the mainstay of treatment whenever possible. Oral prednisone at a dose of 0.5 mg/kg/day is a recommended alternative. In case of contraindications or resistance to corticosteroids, immunosuppressive therapies, such as methotrexate, azathioprine, mycophenolate mofetil or mycophenolate acid, may be recommended. The use of doxycycline and dapsone is controversial. They may be recommended, in particular, in patients with contraindications to oral corticosteroids. B‐cell‐depleting therapy and intravenous immunoglobulins may be considered in treatment‐resistant cases. Omalizumab and dupilumab have recently shown promising results. The final version of the guideline was consented to by several patient organizations.Conclusions: The guidelines for the management of BP were updated. They summarize evidence‐ and expert‐based recommendations useful in clinical practice.
- 17 June 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (12) , 3327-3331.e1
Distinct Metabolite Profile in Pemphigus Vulgaris
- 17 June 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (12) , 3327-3331.e1
Distinct Metabolite Profile in Pemphigus Vulgaris
- 1 June 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (6) , 1552-1564.e8
Multiple Modes of Action Mediate the Therapeutic Effect of Intravenous IgG in Experimental Epidermolysis Bullosa Acquisita
- 1 June 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (6) , 1552-1564.e8
Multiple Modes of Action Mediate the Therapeutic Effect of Intravenous IgG in Experimental Epidermolysis Bullosa Acquisita
- Open Access
- 12 April 2022
- Published by Elsevier in JID Innovations
- Vol. 2 (4) , 100129
How Do Experts Treat Patients with Bullous Pemphigoid around the World? An International Survey
- 12 April 2022
- Published by Elsevier in JID Innovations
- Vol. 2 (4) , 100129
Open AccessHow Do Experts Treat Patients with Bullous Pemphigoid around the World? An International Survey
- 1 December 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (12) , 2820-2828
Pathogenic Activation and Therapeutic Blockage of FcαR-Expressing Polymorphonuclear Leukocytes in IgA Pemphigus
- 1 December 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (12) , 2820-2828
Pathogenic Activation and Therapeutic Blockage of FcαR-Expressing Polymorphonuclear Leukocytes in IgA Pemphigus
- 1 November 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (11) , 2587-2595.e2
Dapsone Suppresses Disease in Preclinical Murine Models of Pemphigoid Diseases
- 1 November 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (11) , 2587-2595.e2
Dapsone Suppresses Disease in Preclinical Murine Models of Pemphigoid Diseases
- Top Cited PapersOpen Access
- 26 July 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (10) , 1926-1948
European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II
This guideline has been initiated by the task forceAutoimmune Blistering Diseasesof the European Academy of Dermatology and Venereology, including physicians from all relevant disciplines and patient organizations. It is a S3 consensus‐based guideline that systematically reviewed the literature on mucous membrane pemphigoid (MMP) in the MEDLINE and EMBASE databases until June 2019, with no limitations on language. While the first part of this guideline addressed methodology, as well as epidemiology, terminology, aetiology, clinical presentation and outcome measures in MMP, the second part presents the diagnostics and management of MMP. MMP should be suspected in cases with predominant mucosal lesions. Direct immunofluorescence microscopy to detect tissue‐bound IgG, IgA and/or complement C3, combined with serological testing for circulating autoantibodies are recommended. In most patients, serum autoantibodies are present only in low levels and in variable proportions, depending on the clinical sites involved. Circulating autoantibodies are determined by indirect IF assays using tissue substrates, or ELISA using different recombinant forms of the target antigens or immunoblotting using different substrates. The major target antigen in MMP is type XVII collagen (BP180), although in 10–25% of patients laminin 332 is recognized. In 25–30% of MMP patients with anti‐laminin 332 reactivity, malignancies have been associated. As first‐line treatment of mild/moderate MMP, dapsone, methotrexate or tetracyclines and/or topical corticosteroids are recommended. For severe MMP, dapsone and oral or intravenous cyclophosphamide and/or oral corticosteroids are recommended as first‐line regimens. Additional recommendations are given, tailored to treatment of single‐site MMP such as oral, ocular, laryngeal, oesophageal and genital MMP, as well as the diagnosis of ocular MMP. Treatment recommendations are limited by the complete lack of high‐quality randomized controlled trials.
- 26 July 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (10) , 1926-1948
Top Cited PapersOpen AccessEuropean Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II
This guideline has been initiated by the task forceAutoimmune Blistering Diseasesof the European Academy of Dermatology and Venereology, including physicians from all relevant disciplines and patient organizations. It is a S3 consensus‐based guideline that systematically reviewed the literature on mucous membrane pemphigoid (MMP) in the MEDLINE and EMBASE databases until June 2019, with no limitations on language. While the first part of this guideline addressed methodology, as well as epidemiology, terminology, aetiology, clinical presentation and outcome measures in MMP, the second part presents the diagnostics and management of MMP. MMP should be suspected in cases with predominant mucosal lesions. Direct immunofluorescence microscopy to detect tissue‐bound IgG, IgA and/or complement C3, combined with serological testing for circulating autoantibodies are recommended. In most patients, serum autoantibodies are present only in low levels and in variable proportions, depending on the clinical sites involved. Circulating autoantibodies are determined by indirect IF assays using tissue substrates, or ELISA using different recombinant forms of the target antigens or immunoblotting using different substrates. The major target antigen in MMP is type XVII collagen (BP180), although in 10–25% of patients laminin 332 is recognized. In 25–30% of MMP patients with anti‐laminin 332 reactivity, malignancies have been associated. As first‐line treatment of mild/moderate MMP, dapsone, methotrexate or tetracyclines and/or topical corticosteroids are recommended. For severe MMP, dapsone and oral or intravenous cyclophosphamide and/or oral corticosteroids are recommended as first‐line regimens. Additional recommendations are given, tailored to treatment of single‐site MMP such as oral, ocular, laryngeal, oesophageal and genital MMP, as well as the diagnosis of ocular MMP. Treatment recommendations are limited by the complete lack of high‐quality randomized controlled trials.